American Society of Hirudotherapy

Roles of oxygen radicals and elastase in citric acid-induced airway constriction of guinea-pigs

Research article published in British journal of pharmacology (1999)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Drug DevelopmentLai YL et al. · British journal of pharmacology, 1999

Abstract

Antioxidants attenuate noncholinergic airway constriction. To further investigate the relationship between tachykinin-mediated airway constriction and oxygen radicals, we explored citric acid-induced bronchial constriction in 48 young Hartley strain guinea-pigs, divided into six groups: control; citric acid; hexa(sulphobutyl)fullerenes + citric acid; hexa(sulphobutyl)fullerenes + phosphoramidon + citric acid; dimethylthiourea (DMTU) + citric acid; and DMTU + phosphoramidon + citric acid. Hexa(sulphobutyl)fullerenes and DMTU are scavengers of oxygen radicals while phosphoramidon is an inhibitor of the major degradation enzyme for tachykinins. Animals were anaesthetized, paralyzed, and artificially ventilated. Each animal was given 50 breaths of 4 ml saline or citric acid aerosol. We measured dynamic respiratory compliance (Crs), forced expiratory volume in 0.1 (FEV0.1), and maximal expiratory flow at 30% total lung capacity (Vmax30) to evaluate the degree of airway constriction. Citric acid, but not saline, aerosol inhalation caused marked decreases in Crs, FEV0.1 and Vmax30, indicating marked airway constriction. This constriction was significantly attenuated by either hexa(sulphobutyl)fullerenes or by DMTU. In addition, phosphoramidon significantly reversed the attenuating action of hexa(sulphobutyl)fullerenes, but not that of DMTU. Citric acid aerosol inhalation caused increases in both lucigenin- and t-butyl hydroperoxide-initiated chemiluminescence counts, indicating citric acid-induced increase in oxygen radicals and decrease in antioxidants in bronchoalveolar lavage fluid. These alterations were significantly suppressed by either hexa(sulphobutyl)fullerenes or DMTU. An elastase inhibitor eglin-c also significantly attenuated citric acid-induced airway constriction, indicating the contributing role of elastase in this type of constriction. We conclude that both oxygen radicals and elastase play an important role in tachykinin-mediated, citric acid-induced airway constriction.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsBody WeightBronchoalveolar Lavage FluidBronchoconstrictionChelating AgentsCitric AcidForced Expiratory VolumeFree Radical ScavengersGuinea PigsPancreatic ElastasePeak Expiratory Flow RateProteins

Summary

Antioxidants attenuate noncholinergic airway constriction.

Why This Matters for Hirudotherapy

This animal study investigated the roles of oxygen radicals and elastase in citric acid-induced airway constriction in 48 guinea pigs, using radical scavengers and enzyme inhibitors. Among the agents tested, eglin-c—described in the abstract only as "an elastase inhibitor"—significantly attenuated citric acid-induced airway constriction, supporting the conclusion that elastase plays a contributing role in tachykinin-mediated bronchoconstriction. This finding is of indirect relevance to ASH's domain only if eglin-c is considered in the context of leech-derived bioactive molecules, though the abstract itself provides no leech origin for eglin-c. The study is not a hirudotherapy investigation; eglin-c is used as a research tool compound rather than a therapeutic intervention, the experiments involve guinea pigs, and the focus is airway physiology. The abstract provides no explicit leech connection.

Citation

Roles of oxygen radicals and elastase in citric acid-induced airway constriction of guinea-pigs

Lai YL et al. · British journal of pharmacology, 1999

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.